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ANTIBODY DEPENDENT ENHANCEMENT:  
A MODEL FOR UNDERSTANDING CONGENITAL ZIKA SYNDROME  
 
EVA EICHEN 
ABSTRACT 
   
 This literature review will discuss Zika virus and the salient research on antibody 
dependent enhancement and how this mechanism may lead to congenital defects. Specific 
objectives include: the mechanism of antibody dependent enhancement, Zika and dengue 
virus pathogenesis, placenta pathophysiology, and how changes in viral virulence may 
play a role the pathogenesis of neurologic congenital defects seen in infants infected with 
Zika virus in utero.  
While some cohort studies have examined the relationship between prior dengue 
immunity, Zika virus infection in pregnancy, and effects on neonatal outcomes further 
prospective studies using large cohorts and more detailed lab testing and imaging is 
essential to better understand this relationship. A proposed study enrolling a large cohort 
of women in the 6th- 8th week of pregnancy from Northeastern Brazil will seek to further 
describe what additional risk dengue immunity may pose in the context of Zika virus. 
This risk is essential to understand, as Zika and Dengue viruses co-circulate in many 
regions of the world. Furthermore, participants in the proposed study will undergo bi-
	 vi	
weekly screening for Zika virus through laboratory and ultrasound testing until their 
delivery. Infants will then have full neurologic testing and MRI scanning for the 
following year after birth to characterize any congenital defects. Neonates born to 
mothers with prior dengue immunity who contract Zika virus during pregnancy will be 
compared to neonates not exposed to Zika virus in utero. This experiment will illuminate 
the associated risk and evidence of ADE occurring with prior dengue immunity and Zika 
virus infection during pregnancy. Results from this study will not only help define risks 
of congenital defects with Zika virus, it will inform vaccine research and elucidate 
challenges in the administration of the current tetravalent dengue vaccine.  	  
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INTRODUCTION 
Background 
Until the 2013 outbreak in French Polynesia, Zika virus had only been known to 
cause benign febrile illness; recuperation was typically fast and self-limiting. However, 
after astounding increases in the number of cases of Guillain-Barré Syndrome, a rare 
autoimmune ascending paralysis, clinicians discovered that in fact, Zika virus was the 
culprit. Equally disturbing, in 2015 Brazilian scientists discovered hundreds of neonates 
born with microcephaly and other profound congenital neurologic defects were caused by 
Zika virus.41, 42 These developments lead the World Health Organization to declare Zika 
virus a public health emergency in 2016, spurring a global effort to research how and 
why some infants infected with Zika virus develop what is now known as Congenital 
Zika Syndrome, a constellation of severe microcephaly, decreased brain tissue and 
subcortical calcifications, joint contractures including arthrogryposis and clubfoot, retinal 
damage, and hypertonia.40 Public health organizations and hospitals struggle to meet the 
extensive medical needs of these children as families also grapple with the emotional and 
physical demands of raising children with Congenital Zika Syndrome.  
 There are many viruses, bacteria, and protozoa capable of causing neurologic 
defects in pregnancy. Namely, the TORCH pathogens: toxoplasma gondii, treponema 
pallidum, rubella virus, cytomegalovirus, herpes simplex virus and others, which are 
regularly screened for in pregnancy.4 Currently, there is still relatively little known about 
the pathogenic mechanisms of how these viruses are passed from mother to fetus. 
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However, there are several unique features of Zika virus which scientists postulate may 
be implicated in its pathogenesis.  
One of the salient hypothesis used to describe the increased virulence of Zika 
virus has to do with prior immunity to Dengue virus, a virus transmitted by the same 
Aedes aegypti mosquito and endemic in many of the same regions as Zika virus. 
Scientists believe pre-existing dengue antibodies may predispose individuals to Antibody 
Dependent Enhancement (ADE) upon infection with Zika virus. 22, 23, 25, 27, 28 ADE occurs 
when circulating non-neutralizing antibodies to Dengue virus recognize Zika virions, 
which then signals them to be preferentially taken up by Fc receptor presenting cells such 
as macrophages and dendritic cells. Instead of these cells destroying the opsonized Zika 
virus, host machinery replicates more copies of Zika virus leading to increased viremia.25 
ADE is a mechanism thought to be utilized by many viruses such as Dengue and Human 
Immunodeficiency Virus. Scientists believe the reason severe dengue infections 
(hemorrhagic fever and shock) occur is due to ADE when the body is re-exposed to a 
slightly different dengue strain.38 Furthermore, scientists question if ADE could explain 
why some pregnancies infected with Zika virus result in neurologic defects and why 
others result in normal infants.31  
 
Statement of the Problem 
During the 2013 French Polynesia and 2015 Brazilian outbreaks of Zika virus, a 
remarkable increase in the number of neonates born with microcephaly and other 
congenital neurologic problems was observed.42 Later it was determined that Zika virus 
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infection during pregnancy was the causative agent; however, not all neonates born to 
Zika infected mothers had evidence of neurologic deficits, and the severity of deficits 
varied. Scientists have hypothesized that the antibody dependent enhancement 
mechanism where poorly neutralizing, cross-reactive anti-dengue antibodies cause 
increased Zika virus replication contributes to the range of severe clinical manifestations 
when Zika virus infection occurs in pregnancy. 27, 28, 32, 40 
 Autopsy reports seen in cases congenital Zika infection suggests that ZIKV 
antigens, RNA, and non-neutralizing antibodies may be passed through the placenta 
targeting fetal neuroprogenitor cells.3,11 In addition, virulence factor changes making 
humans particularly susceptible to Zika virus infection or the genetic variability in 
humans’ innate immune system may account for the recent increase in fetuses affected by 
Congenital Zika Syndrome.35, 36 Other factors such as increased virulence of the Zika 
virus, and its specific adaptation to humans may also contribute to why some pregnancies 
infected with Zika virus result in neurologic malformations.   
 
Hypothesis 
Antibody dependent enhancement of Zika virus after prior Dengue virus infection 
may lead to the development of Congenital Zika Syndrome; however, other factors such 
as host genetic variation and enhanced adaptation of Zika virus to humans may also 
explain the recent increase in congenital neurologic defects seen in pregnancies infected 
with Zika virus.  
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Objectives and specific aims 
This literature review will examine the current knowledge of Zika and Dengue 
viruses, the mechanism of antibody dependent enhancement, and the clinical and in vitro 
evidence used to support and challenge antibody dependent enhancement in Zika virus 
with pre-existing dengue immunity. By examining the similarities between dengue and 
Zika viruses and proposed mechanisms of Zika pathogenesis, the range of data to support 
how Zika virus affects the placenta, as well as examination of the case studies of 
Congenital Zika Syndrome it will become clearer why antibody dependent enhancement 
is an essential mechanism to understand. Furthermore, analysis of antibody dependent 
enhancement will have important impacts on the future of dengue and zika virus vaccine 
candidates and therapeutics. 
Objectives: 
- Discuss the experimental evidence for antibody dependent enhancement in 
Zika virus with pre-existing dengue antibodies	
- Discuss the range of congenital defects seen in Zika virus, Zika virus 
pathophysiology, and other viruses serving as models for understanding Zika 
virus	
- Propose a prospective cohort study involving women presenting between 6 
and 8 weeks of pregnancy who are at risk for Zika virus infection	
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REVIEW OF THE LITERATURE 
Overview 	
Original Antigenic Sin 
In 1960 Dr. Thomas Francis Jr., described the theory of “original antigenic sin” 
which states that after prior exposure to a virus, the immune response to a different 
serotype of that virus may be insufficient, resulting in more severe disease.52 The immune 
system when challenged with a heterotypic serotype may be unable to distinguish the two 
serotypes. Instead of adapting, the humoral immune system produces antibodies against 
the first serotype from its memory. 52 He postulated that depending on age group, subjects 
would have primary antibodies to the particular strains of influenza circulating at the 
time. 52 
To test this hypothesis, Francis examined immunity to Influenza A in different 
age groups in 1960. He took serum from a random sample of 1,250 people, and found 
that antibodies to subtypes of influenza were only present in the population that would 
have been exposed when that virus was circulating. 52 For example, Francis found that 
antibodies to the “original A group” were highly detectable in 20 year olds corresponding 
to the period between 1932 -1936 when that type A influenza was first isolated. Whereas 
in children less than 10 years old, those antibodies were not isolated because the last 
exposure to that strain was between 1943 and 1952, before those children were born.  
Original antigenic sin affects both the adaptive and innate immune systems. 
Normally, when the body is invaded by a pathogen the innate immune system recognizes 
that pathogen as foreign and they signal to antigen presenting cells (APCs) that backup 
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from the adaptive immune system is needed. The APCs then endocytose the pathogen 
and display pieces of it on through their MHC-II complexes which are recognized by a 
specific T cells. 18 Through clonal expansion, effector B-cells produce antibodies, while 
effector T cells which destroy pathogens via cytokines and enzymes are activated, and 
memory B cells and memory T cells are produced.18 This primary response process is 
slow and takes approximately two weeks to complete and occurs when the immune 
system is challenged with any completely unknown pathogen.  
If a second infection to the same pathogen occurs, the memory B and T cells are 
quickly activated, antibodies are produced and clinical manifestations are milder. 
Original antigenic sin comes into play when the immune system is challenged with a 
slightly different virus. Conflating the new virus with the old, the memory T and B cells 
react to this slightly different pathogen as if it were exactly the same antigen they had 
seen in the first infection, and do not mount an immune response directly against the new 
pathogen. 18 This may lead to failure of the immune system to clear the infection resulting 
in dire and even fatal consequences for the individual.  
Antibody dependent enhancement 
Antibody dependent enhancement (ADE) builds off the theory of original 
antigenic sin and is a central argument used to explain the severe effects of dengue after 
serial infections and is a proposed mechanism for ZIKV pathogenesis.38 It is a 
phenomenon proposed to occur with HIV, influenza and other pathogens whereby a 
subject gets infected with a primary virus and creates protective antibodies against that 
strain but when infected by another slightly different serotype, those antibodies are not 
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effective in neutralizing the virus.25 Antibodies opsonize the viral proteins and then Fc 
receptor bearing cells such as macrophages, monocytes and dendritic cells endocytose 
those virally infected cells via the Fc receptor, and instead of trafficking to the lysosome 
to be destroyed, they replicate inside these cells. 25 When the phagocytes replicate more 
viral progeny, it can cause a more serious infection. The following literature review will 
explore this mechanism in depth.  
Figure 1. Conceptual mechanism of “original antigenic sin” 18 
		
Fig.2. Conceptual mechanism of “original antigenic sin”. Response to exposure to two similar serotypes 
[of] virus. Serotype 1 antigen is processed and presented by the antigen presenting cells (i.e. dendritic cells 
–DC’s-) leading to the priming of the B and T lymphocytes, and subsequent clonal expansion of serotype 1 
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specific lymphocytes. This clonal expansion is cross-reactive, and occurs even upon exposure to serotype 2, 
rendering an ineffective response against the serotype 2.18 
Original figure from Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya J-M, Gershwin ME. Original 
antigenic sin: A comprehensive review. Journal of Autoimmunity. May 2017. 
doi:10.1016/j.jaut.2017.04.008. 	
Evidence Supporting Antibody Dependent Enhancement in Dengue Virus 
 Dr. Scott Halstead, an American physician and expert on dengue virus has 
advocated for the hypothesis of antibody dependent enhancement. One of his most 
significant studies was a longitudinal epidemiological study to investigate dengue 
hemorrhagic fever in Rayong, Thailand between January and April 1980. In that study, 
4,136 baseline blood samples from children <1 to 14 years with previous dengue virus 
infection were collected. 38 During that year, 8 of those children were hospitalized for 
Dengue Shock syndrome, now known as severe dengue shock. For these children, one 
blood sample was taken acutely and another was collected in the convalescent phase. 
Blood samples from seven children were taken 3-5 months after their acute illness. Then, 
hemagglutination-inhibiting antibodies from the children were tested against DENV2 and 
DENV4 antigens to test neutralizing capacity. Plaque reduction neutralization (PRNT) 
tests were performed when antibodies were introduced to dengue virus suspension. 
Antibody titers over time showed that all seven subjects demonstrated secondary-
type antibody response.38 Each subject had increased neutralizing antibody titers to the 
original serotype they were exposed to in both the acute and convalescent phases. For 
example, subject 94 had a primary antibody titer of 144 in the pre-illness phase and when 
he/she presented with severe dengue, titers increased to 1,920 to D1 but much lower titers 
than D2, D3, and D4. 38 Finally, in the late convalescent phase, subject 94 had an even 
higher prevailing antibody titer at 2,400 whereas the three other titers were considerably 
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lower.38 These results support the hypothesis that repeat infection with dengue virus 
increases titers of the original infecting serotype. 
Table 1: Reciprocal PRNT in Serum Specimens, adapted from Halstead et al 1980 38 
            
  
Pre-illness (Jan 1980) 
  
  
  
  
Acute Phase 
  
  
  
  
  
Late Convalescent Phase 
  
  
  
Dengue 
Serotype 
                          
Subject 
No D1 D2 
D
3 
D
4 
Day 
after 
onset D1 D2 D3 D4 
Month 
after 
onset D1 D2 D3 D4 
6 0* 0 0 56       N.D.   8 0 80 0 98 
49 0 0 71 0 4 1,700 1,700 2,300 680 5 40 80 3,500 86 
52 32 0 0 0       N.D.   3 420 380 110 30 
84 46 0 0 0 7 1,920 310 1,520 240 3 2500 720 1401 200 
86 158 0 0 0 3 2,500 1,920 2,000 450 5 240 100 130 80 
94 144 0 0 0 4 1,920 600 920 80 4 2400 300 1920 80 
120 0 0 31 0 6 160 1,920 2,000 110 3 600 700 4000 380 
               
"Dengue virus neutralizing antibody titers in pre-illness, acute phase, and late convalescent sera 
from dengue shock syndrome cases, Rayong, Thailand, 1980."38    
               	
 This study documented seven cases where primary dengue infection lead to a 
specific increase in the serotype of original infection after exposure to a second dengue 
serotype supporting the theory of original antigenic sin. However, Halstead reported on 
an extremely small number of cases out of the 4,136 original samples collected. He does 
not identify if those were the only cases of severe dengue that occurred or if those were 
the only cases that presented to the hospital. This important distinction eliminates the 
possibility of a selection bias in the data. Moreover, the few cases that he was able to 
report on are not enough to show statistical significance to support the hypothesis that 
original antigenic sin with serial Dengue virus infection occurs in the majority of severe 
dengue cases.  
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A more recent study done in 2004-2006 in Ho Chi Minh City, Vietnam by 
Simmons et al examined the relationship between maternal antibodies and viral factors in 
the pathogenesis of severe dengue infection in 55 full-term infants with suspected 
dengue. Using ADE as a model hypothesis to understand dengue hemorrhagic fever and 
dengue shock syndrome (DHF/DSS) the authors postulated that maternal antibodies to 
DENV would provide partial protection to infants in the first months of life, but once 
immunity wanes, sub-neutralizing concentrations of antibodies could enhance infection 
of Fc receptor cells, and that increasing viral loads would stimulate the immune response 
to produce inflammatory cytokines and vasodilators that cause increased permeability of 
vessels leading to the symptoms of DHF and DSS.17 They hypothesized that infants 
presenting to the hospital with dengue fever symptoms would have decreased levels of 
maternal neutralizing antibodies and increased levels of viremia.  
Confirming their hypothesis, Simmons et al found that 65% of infants 
experienced hemorrhagic fever when their maternal antibody titers were less than 1:20, 
but there was no association between serotype-specific neutralizing antibody titers in the 
mother and the age at which their infants experienced dengue.17 In addition, investigators 
found that patients with similar disease severity had extremely variable viral load levels. 
They note that one cohort of DHF patients had viral load copies of more than 106 copies 
of DNA/mL whereas other patients including those with DSS had 1000-fold lower viral 
loads on the same day in their illness progression. 17 Infants displayed varying levels of 
virus and non-structural protein 1 (NS1), a DENV viral antigen, in infants with severe 
dengue and that these levels were independent of each other. 
	 	 	 	
	 	 	 	11	
Assuming that ADE were the mechanism at play, it would seem plausible that 
infants with severe DENV symptoms would have low levels of maternal antibodies, and 
higher levels of virus in the blood. Since this was not the case, investigators took this to 
mean that a more complex pathogenesis must be occurring; that the disease 
manifestations must involve host genetic or innate immune responses. 17 However, the 
authors maintain that DHF has not yet been described in an infant born to a dengue-naïve 
mother, underlining the fact that pre-existing immunity to DENV must play a role in 
severe dengue. 17 To that end, Simmons et al cite epidemiological data that show that 
infants less than 12 months, children greater than 3 years, and young adults comprise 
most of the DHF cases in Vietnam. 17  
Simmons and colleagues originally proposed that severity of dengue in infants 
would have positive association with viral load, but on the contrary, they found no 
encompassing trend in levels of viremia in infants with severe dengue. 17 In their 
discussion, they note that their findings may have been due to problems in predicting the 
plaque reduction neutralization titers (PRNT) at the time of the infant’s DENV infection. 
They utilized PRNT to estimate at what level their maternal antibodies were when they 
experienced acute DENV disease, but the fact that a small cohort of infants less than 6 
months developed dengue hemorrhagic fever even though their predicted maternal 
antibodies were still high suggests that either the PRNT testing is not accurate, or that 
there are other factors such as variation in host immune response, genetic predisposition, 
or the size of the inoculum that determine infection outcomes. 17 Others have described 
the role of innate immune responses such as high levels of TNF-a, IFN-y, IL10 and IL16 
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in severe dengue infection. 14, 17 Simmons et al note the plausibility for some individuals 
to produce these cytokines in response to infection may be involved in some of the 
disease variation seen in dengue infection. 
Other investigators similarly question the data that is used to support ADE as is 
relates to clinically severe forms of dengue infection. Vatti et al write that perhaps other 
factors such variability in adaptive immune system mechanisms contribute to 
pathogenesis.18 Investigators have seen that T-cell responses may be protective against 
more severe dengue infections. For example, they cite studies finding that Th-1 memory 
T cells responding to IFN-γ is associated with less severe secondary DENV infection, 
while secretion of TNF-α, leads to a more severe response. 18  
Taken together, investigators do not discount the possibility of ADE in the 
pathogenesis of DENV, but they still question the clinical data supporting the claims.18 
Future clinical studies similar to those conducted by Simmons in large and diverse 
populations are needed to better establish if pre-existing antibody seropositivity leads to 
more severe dengue infection. It is likely that with the development of the new dengue 
vaccine long term follow up studies will examine if the pre-existing immunity in certain 
age groups or populations is correlated with more severe disease outcomes.   
Development of the Dengue Vaccine 
For some time, the possibility of creating a vaccine against dengue virus was 
deemed impossible due to the problem of serial enhancing infections, multiple serotypes, 
and difficulty in finding immunogenic targets.19 This all changed when in 2014 a phase 
three trial on the Sanofi Pasteur live attenuated tetravalent dengue vaccine, Dengvaxia, 
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was published.19 The study involved 10,275 children ages 2-15 years in Asia, and the 
vaccine efficacy was calculated at 56.5%.20 Importantly, the risk of hospitalized dengue 
was significantly higher in the 2-5 year old age group.21 The relative risk for the 2-5 year-
old age group was 7.45 CI: 95% whereas relative risk for the 6–11 and 12–14 year age 
groups was 0.627 and 0.249 respectively. 21 For this reason, Sanofi Pasteur has excluded 
children ages 9 and under from the licensure request. It was also found that the vaccine 
efficacy in this trial was lower in DENV naïve patients.21 Given this data, the World 
Health Organization and other investigators have brought in to question whether antibody 
dependent enhancement is responsible for the increased risk in severe dengue infection in 
young children.21 In the future, long term studies on the Dengvaxia vaccine will require 
all participants to have serologic testing determining DENV immunity before enrollment.  
A second study on the dengue vaccine performed in Latin America involved 
20,869 healthy children ages 9-16 years who received either the vaccine or placebo in a 
two to one ratio.19 Participants from Mexico, Brazil, Honduras, Puerto Rico, and 
Colombia were monitored for 25 months overall. The vaccine efficacy was calculated as 
60.8% against symptomatic dengue after three doses of the vaccine in children 9-16, and 
the efficacy against hospitalization was 80.3%.19 In a subset of children enrolled, 79.4% 
had previous DENV exposure to one or more serotypes. 19 While a large number of 
children in this area had improved rates of prevention of hospitalization and symptomatic 
disease, many of these children had some previous dengue exposure. Due to the WHO 
mandate, patients under the age of 9 were excluded from this study making the 
generalizability and feasibility of this vaccine more questionable.19 
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 Long-term efficacy and safety studies of this vaccine will surely contribute more 
clinical data to the understanding disease enhancement. Despite the protection this 
vaccine has offered in dengue exposed individuals, many scientists and clinicians alike 
are concerned about the possibility of either dengue or ZIKV enhancement once the 
vaccine has become more widely used.22, 23 Without completely discounting the effect of 
disease enhancement, vaccination could increase the risk of more severe ZIKV infections 
in children. Further studies on the Dengvaxia vaccine and the increasing number of 
people infected with ZIKV will likely shed light on the association between prior 
immunity to DENV and either more severe dengue or zika infections.   
 
Existing Research 
Support for Antibody Dependent Enhancement and Zika Virus 
Given the extensive literature and clinical evidence suggesting the plausibility of 
ADE pathogenesis in DENV, it is possible a similar mechanism occurs with ZIKV. The 
homology between the DENV and ZIKV, similar mechanism of pathogenesis, disease 
vectors and locations where the viruses are endemic leads researchers to believe that 
synergy between the two viruses is responsible for the severe effects of ZIKV infection in 
neonates.25, 31 In some areas in Brazil where ZIKV outbreaks have occurred, DENV 
seroprevalence is high, making it plausible that many women whose offspring experience 
congenital abnormalities due to ZIKV could have enhancing immune response to the 
viral infection.24 While in theory this hypothesis seems plausible, it is difficult to explore 
clinically.  
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Researchers have used mice and rhesus monkey models to demonstrate ADE with 
ZIKV, however, results are limited and often conflicting.18, 22, 26, 27, 28,30,32 It is difficult to 
correlate viremia and other markers with disease severity as in DENV. Other hypotheses 
including host genetic predisposition, and viral mutations have also been proposed to 
explain the increase in congenital malformations associated with ZIKV.30, 35, 36, 37 
Whether or not ADE is implicated in the fetal outcomes of ZIKV infection, it is essential 
to evaluate this question within the context of vaccines and prevention. If dengue 
vaccinated individuals are predisposed to a more severe Zika viral syndrome, or equally 
concerning vice-versa, where zika immune individuals are exposed to more severe 
dengue infections the numbers of cases of severe dengue and congenital neurologic 
defects could increase leading to public health emergencies.  
 
Proposed mechanism of Antibody Dependent Enhancement in Zika virus 
 Researchers Heinz and Stiasny have theorized that ADE occurs with ZIKV in the 
following manner. A dengue-immune person with low levels of anti-dengue antibodies is 
infected with Zika virus. This individual’s anti-dengue antibodies recognize and cross-
reacts with Zika viral antigens but are unsuccessful in neutralizing Zika virus opsonize on 
the surface of the virus. They attract Fc receptor expressing cells to phagocytose the 
viral- immunoglobulin complexes. Once monocytes, macrophages, and dendritic cells 
endocytose antibody-virus complexes, viral production is enhanced by utilizing host cell 
machinery.25 Zika virus can fuse with the host cell endosome, and instead of the virus 
being digested; it is able to utilize host cell machinery to replicate more viral copies. 25 It 
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is possible this mechanism could work both ways with Zika enhancement as well as prior 
zika immunity causing DENV enhancement. Antigenic variance in flavivirus replication 
helps explain why antibody dependent enhancement may not be observed in all patients 
with serial dengue infections of pre-existing dengue immunity and subsequent ZIKV 
infection. 
Barba-Spaeth and colleagues in their Nature paper, discuss the immunogenic 
properties of the flavivirus family and why ADE may not be observed in all cases of 
flavivirus infection.26 The investigators characterize three well-conserved proteins 
expressed on the surface of flaviviruses. First, the envelope protein (E protein) mediates 
fusion between the host and viral cell, second, the precursor membrane protein (prM), 
and third, the fusion loop epitope (FLE), a dominant cross-reactive antigenic site. 26  
Barba-Spaeth et al hypothesize that FLE proteins are implicated in ADE because 
they are poorly neutralizing, thus allow for increased viral replication while E proteins 
are main targets of neutralizing antibodies. 26 When the prM is cleaved the E protein 
under the influence of the endosome’s pH changes conformation causing fusion of the 
viral and endosomal membranes, thus releasing the viral RNA into the host cell 
cytoplasm. 26 Through the process of viral cell “breathing” when the prM protein is 
cleaved, it allows the E protein to change location, and in doing so allows exposure of 
other proteins such as the FLE protein.26 Experimentally, investigators found that FLE 
antibodies, which neutralize DENV, do not neutralize ZIKV even at high 
concentrations.26 Cross-reactive antibodies to the FLE protein are common in DENV 
immune sera but only weakly neutralize ZIKV because the antibodies bind only when the 
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E protein shifts location. Furthermore, the change in membrane proteins to expose FLE 
may explain why ADE is not always observed in vivo, or why some individuals may 
experience severe dengue after serial infections, and some do not.  
One of the most compelling supports for ADE of ZIKV comes from a study 
performed in Thailand with a population of children that were previously involved in a 
study regarding acute dengue virus infection. Dejnirattisai et al collected plasma and 
peripheral blood mononuclear cells (PBMC) from 18 children ages 2-15 years in Khon 
Khaen, northern Thailand.27 Serum samples during acute dengue infection and 
convalescent phases (approximately 6 months after infection) of disease were collected. 
Using ELISA, all cases showed that DENV immune plasma had antibodies that 
interacted with both DENV and ZIKV. In the convalescent plasma, they found antibodies 
also neutralized DENV 100% at the lowest dilution (1:50) but when they tested 
convalescent plasma against ZIKV most plasma showed no appreciable neutralization at 
a 1:50 dilution except for three samples. 27 This showed that serum from DENV immune 
patients had limited neutralizing power against ZIKV infection. 27 Next, the researchers 
wanted to see if DENV induced ADE in U937 myeloid cells, a resistant cell line except 
in cases of ADE.  
When ZIKV was pre-incubated with convalescent serum 1-2 weeks after acute 
DENV infection and inoculated in myeloid cells, this lead to more than a 100-fold 
increase in the ZIKV strains PF13 and H78788 (French Polynesia and African strains, 
respectively) compared to controls. 27 Carrying out the same process with convalescent 
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sera from subjects 6 months after their infection, in all but one case, Zika virus infections 
increased 12 fold of the median for strain African strain HD78788. 27  
To further identify how specific antibodies were involved in cross reaction with 
ZIKV or enhancing Dejnirasattai et al used a specific panel of human mAbs to DENV 
envelope protein made from Dengue infected persons. 27 There were three reactive 
categories for these antibodies. One third of mAbs responded to the fusion loop (FLE), 
another third reacted to the envelope, these were designated non-FLE mAbs, and the last 
third bound only to intact virus, these were the envelope dimer epitopes (EDE) 
subdivided into groups 1 and 2. 27 Through x-ray crystallography, these EDE antibodies 
were shown to bind to a quartenary epitope which is made by two envelope monomers. 
Binding of the panel of anti-DENV mAbs to ZIKV was done with capture ELISA and 
then this was compared that with the binding to DENV alone. Binding of the antibodies 
to the African (HD78788) and the French Polynesian (PF13) strains of ZIKV was similar. 
27 Investigators also found that all of the FLE mAbs cross-reacted with ZIKV, 36 out of 
37 non-FLE Abs reacted with ZIKV, but the EDE1 and EDE2 mAbs response was more 
variable. 27 Whereas 27 out of the 33 EDE1 mAbs were able to bind only 8 out of the 17 
EDE2 mAbs bound ZIKV. 27 Binding curves showed EDE1 had higher affinity for ZIKV 
than EDE2. Taking this information into account, the investigators were able to say that 
all of these monoclonal antibodies were cross reactive with ZIKV, making all of them 
candidates for enhancing replication.27  
The next step was to test whether these anti-DENV mAbs incubated with U937 
myeloid cells and then infected with infected with ZIKV could induce ADE. Three of the 
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mAbs to FLE that were completely non-neutralizing of ZIKV showed ADE enhancing 
39-91 fold of the African strain of ZIKV. Likewise, the mAb to EDE induced ADE of 
ZIKV when added at sub-neutralizing concentrations. Thus, the different mAbs types had 
broad cross-reactivity to ZIKV and were able to induce enhancement of the ZIKV 
infection in myeloid cells. 27 In sum, the results of this study showed that in myeloid cell 
culture using human mAbs, the vast majority of Abs to DENV were cross reactive, non-
neutralizing and enhancing of ZIKV via antibody dependent enhancement.  
This study provides evidence to support that there are many non-neutralizing 
cross-reactive antibodies to DENV that induce antibody dependent enhancement with 
Zika virus. While investigators did use myeloid cells that were specifically designed be 
infective in the presence of ADE, the data would have been more convincing in support 
of ADE if a wild type animal model were used. To test this hypothesis in a living animal 
would be difficult but is necessary to show that ADE does in fact occur in vivo. 
Lauren Paul and colleagues report similar results regarding the capabilities of 
Dengue monoclonal antibodies (mAbs) and human serum to enhance ZIKV infection in 
rhesus macaque kidney epithelial cells.28 Paul’s data support the hypothesis that anti-
DENV mAbs are cross-reactive with ZIKV, incapable of neutralizing, and enhance ZIKV 
in vitro. When compared with DENV immune plasma, investigators found that mAbs 
caused varied neutralization against ZIKV and to a similar degree enhanced ZIKV 
infection.28 Using two mAbs against the viral antigen E protein, 1.6D, and fusion loop 
protein, D11C (which had previously been established to be conserved among the two 
viruses) researchers designed their study to discover if ZIKV infection in rhesus macaque 
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kidney epithelial cells could be neutralized. Subsequently, they found that neither type of 
mAbs were able to neutralize ZIKV. 28 Comparing the 1.6D and D11C to an anti-ZIKV 
neutralizing Ab, even at increasing concentrations, there was still no neutralization of 
ZIKV with mAbs. 28 In testing another ZIKV isolate from Puerto Rico, PRVABV59, 
using RT-PCR Paul et al observed that viral progeny was greatly enhanced when in the 
presence of 1:50,000 dilution of DENV Singapore strain 1 when there was a greater than 
1800 fold increase in genome copies. 28 Paul and colleagues observed strong viral 
replication enhancement when ZIKV was incubated together with the DENV immune 
sera in the rhesus epithelial cells by up to 200-fold. 28 
In vivo studies supporting ADE with ZIKV  
A case report in the New England Journal of Medicine by Driggers et al recounts 
the history of a Finnish woman who traveled to Mexico, Guatemala and Belize during her 
11th week of pregnancy and contracted Zika virus. She had manifestations of ZIKV 
infection at approximately 12.3 weeks gestation, 10 days after her arrival back home to 
Finland. 29 The patient developed mild fever (37.5 degrees for 5 days), myalgias, eye pain 
and rash. During the symptomatic period, the fetal ultrasound revealed normal fetal head 
size and anatomy. Subsequently, at 19 weeks the fetus was diagnosed with cortical 
atrophy, microcephaly (24th percentile decreased from 47th percentile at 16 weeks) and 
ZIKV RNA was present in the amniotic fluid. 29 The pregnancy was terminated at 20 
weeks. Her spouse reported similar symptoms around the same time but had negative 
serum and urine ZIKV RNA tests at 5 and 11 weeks, and negative semen ZIKV RNA at 
	 	 	 	
	 	 	 	21	
10 and 12 weeks after travel. However, the patient’s spouse ZIKV IgG (titer 320) and 
IgM (titer 20) were both positive.29 
The lab testing for this patient is indicative of possible ZIKV enhancement.  At 16 
weeks, the patient’s serum sample found negative DENV IgM but positive IgG in excess 
of 1000. 29 She also had both ZIKV IgM and IgG present. Her plaque reduction (PRNT) 
tests were higher for ZIKV than DENV. The patient’s serum ZIKV RNA was detected 
well into her 20th week of pregnancy. 29 Driggers et al point out that the persistent ZIKV 
viremia, since the patient had positive ZIKV RNA testing 9 weeks past the point of acute 
infection, when normally ZIKV RNA is not detectable past 2 weeks, was a consequence 
of high viral loads due to high replication in the fetus or placenta. 29 To rule out other 
causes of neuropathology, the patient had CMV, toxoplasma gondii, HSV, rubella virus, 
and parvovirus B19 serum antibody testing, all of which were negative. She had negative 
serum tests for chikungunuya, and the patient had been vaccinated against tick-borne 
encephalitis and yellow fever virus approximately 10 years prior.29 These findings and 
clinical presentation together suggests that the patient had an acute ZIKV infection.  
More thought provoking are the patient’s dengue antibody lab results, which can 
be interpreted two different ways. One, the patient was dengue immune for a longer 
period of time than she was for ZIKV, or two, she had been co-infected with ZIKV and 
DENV but her IgGs to DENV developed more quickly. However, the time period 
between primary and secondary DENV infections is important for the disease 
manifestations.30 Immunity to a slightly different DENV serotype can be protective for 
up to 6 months, whereas enhanced disease is usually seen in second infections 12 months 
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or more after a first infection.30 It is unclear if the same works for DENV and ZIKV. 
Since it is unknown when this patient was exposed to DENV, perhaps it would be too 
soon for disease enhancement to take place.  
Figure 2: Timeline of Symptoms and Radiographic and Laboratory Evidence 29 
 
This timeline highlights the symptoms of Zika virus (ZIKV) infection in the mother (bottom row) and the 
corresponding radiographic and laboratory findings in the fetus (top row). The inset photograph shows the 
mother’s rash at the time of the acute illness. DENV denotes dengue virus, MRI magnetic resonance 
imaging, PBMC peripheral blood mononuclear cells, and PRNT plaque-reduction neutralization test.29 
 
Originally from Driggers RW, Ho C-Y, Korhonen EM, et al. Zika Virus Infection with Prolonged Maternal 
Viremia and Fetal Brain Abnormalities. New England Journal of Medicine. 2016;374(22):2142-2151. 
doi:10.1056/NEJMoa1601824. 
 
 
Given the patient’s persistent ZIKV RNA in serum and levels of antibodies, it is 
possible this patient may have experienced a more acute ZIKV infection due to previous 
DENV immunity. Normally, 80% of patients do not experience ZIKV symptoms, 
however, this patient had an acute clinical presentation.30 Taken together, perhaps the 
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persisting ZIKV RNA titers, ZIKV IgM and IgG, and DENV IgG contributed to the 
neuropathology in the fetus. It is also possible this patient was co-infected with DENV 
and ZIKV, but regardless, the subject still had higher levels of ZIKV RNA, and more 
potent antibodies ZIKV than DENV as evidenced by PRNT testing. 30  
 This case study highlights an important population to study. More research to 
correlate the effects of previous DENV infection, ZIKV infection on fetal outcomes is 
necessary to better characterize ADE in vivo. In this patient, there was clearly a more 
enhanced ZIKV immune reaction, but whether her previous exposure to DENV played an 
enhancing role is unclear. Discussion of a proposed study later on will focus directly on 
answering this crucial question.  
Challenges to ADE in ZIKV 
 Several studies have challenged the mechanism of ADE for failure to reproduce 
results of ZIKV enhancement both in vitro and in vivo using animal and human models. 
Furthermore, some investigators question the relevance and significance of data on 
Dengue viral enhancement that was collected many years ago. It is essential to examine 
other the arguments and data which point to alternative reasons for why Congenital Zika 
Syndrome is seen in some but not all pregnancies.  
Halai and colleagues from UCLA and Fundação Oswaldo Cruz in Rio de Janeiro, 
Brazil recently published a prospective cohort study involving 345 pregnant women to 
test if the association between clinical disease severity, congenital birth defects, and prior 
dengue virus immunity.31 Out of the 345 pregnant women suffering a new-onset rash, 
53% tested positive for ZIKV via urine and/or serum PCR testing. 31 134 women positive 
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for ZIKV were followed until May 2016 and 125 of the pregnancy outcomes were 
recorded. Clinical severity was scored based on four categories: severity of rash, duration 
of fever, multisystem involvement, and duration of illness. For each category, women 
were scored 1 being mild and a maximum of 3 for severe. Then the individual scores 
were calculated together and graded mild, moderate, and severe for total scores of 4 or 
less, 5-8, and 9-12 respectively. 31 There was 88% seropositivity for at least one Dengue 
strain in the Zika positive cohort. 31  
 The first finding, corroborated by other studies shows that the greatest risk for 
fetal abnormalities occurs in early gestational period.2 Halai and colleagues calculated a 
protective effect of ZIKV infection later on in gestation (p=0.042). 31 Every week of 
pregnancy reduced the odds of abnormal outcomes by 5%.31 Other significant findings 
were that no association was found between disease severity and abnormal outcomes 
(p=0.961), disease severity and viral load (p=0.994), or viral load and adverse fetal 
outcomes (p=0.667). 31 Most relevant to this discussion, there was no association found 
between prior dengue exposure and disease severity, ZIKV-RNA viral load or adverse 
fetal outcomes (p=0.667). 31 These data lead the investigators to believe that congenital 
defects due to ZIKV infection are not associated with increasing disease severity, ZIKV 
viral load, or exposure to Dengue virus therefore inconsistent with antibody dependent 
enhancement.31 
Table 2: “Baseline characteristics of ZIKV PCR positive women” 
 
Category N Percentage Range 
Median age (years) 31   16-46 
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Median gestational 
age at infection 
(weeks) 
24  6-39 
First trimester 
infections 
16/134 11.9%  
Second trimester 
infections 
74/134 52.2%  
Third trimester 
infections 
44/134 32.8%  
Signs and Symptoms    
Fever 34/124 27.4%  
Fever lasting >2 days 4/124 3.2%  
Rash    
Mild 31/131 23.6%  
Moderate 65/131 49.6%  
Severe 35/131 26.7%  
Neurologic 
symptoms (Headache 
or photophobia or 
retro-orbital pain or 
tremor or 
paresthesias) 
92/131 70.2%  
Gastrointestinal 
symptoms (Anorexia 
or nausea/vomiting 
or abdominal pain or 
diarrhea 
70/131 53.4%  
Fatigue or 
lightheadedness 
68/131 58.2%  
Myalgia 53/130 36.9%  
Arthralgia or arthritis 
or peri-articular 
edema 
81/131 62.3%  
Lymphadenopathy 48/125 38.4%  
Edema 54/99 54.5%  
Conjunctival 
injection 
73/127 57.5%  
Multisystem 
involvement other 
than fever and rash 
   
1-2 systems 47/134 35.1%  
3-4 53/134 39.6%  
>5 34/134 25.45%  
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Median duration of 
symptomatic illness 
7   3-68 
Duration < 5 days 43  32.8%  
Duration 6-9 days 60 45.8%  
Duration > 10 days 28 21.4%  
Median day of 
symptoms at 
evaluation 
4   1-31 
 
Original work with data from original study: “Maternal Zika Virus Disease Severity, 
Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes” Halai 
et al 2017. 
 
 
Table 3: Main Outcomes of a Prospective Cohort Study of Zika Virus Infected 
Pregnancies in Women with Previous Dengue Virus Exposure 
 
Outcomes N Percentage 
ZIKV-PCR positive 
pregnant women 
131 100% 
Mild disease 6 4.6 
Moderate disease 98 74.8 
Severe disease 27 20.6 
Abnormal outcomes (out 
of 125) 
58 46.4 
Structural or imaging 
abnormalities (ZIKV) 
37 29.4 
Abnormal neurological 
assessments 
12 9.5 
Live births 117  
Fetal losses  9 7.2 
Prior dengue antibodies 117 88 
 
Original work with data from original study: “Maternal Zika Virus Disease Severity, 
Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes” Halai 
et al 2017. 
 
 Although this prospective study provided significant evidence to refute the 
hypothesis that prior dengue immunity leads to more severe congenital defects, this study 
had a very small sample size of 134 women, and inclusion criteria mandated that subjects 
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be symptomatic.31 However, the data demonstrated no measurable association between 
clinical disease severity and risk for congenital defects. 31 Furthermore, a larger 
prospective study including both symptomatic and asymptomatic pregnant women in a 
similar trial would provide more evidence to understand the association between presence 
of DENV antibodies, ZIKV infection, and risk of congenital defects. 
 Advanced imaging techniques were not utilized for this study, as neurologic 
deficits associated with Zika virus infection in the neonate are possible to diagnose 
clinically. Furthermore, the cost and location of these advanced imaging techniques make 
their use prohibitively expensive. The proposed study, Mãe Sana, Bebé Sana, will not 
utilize advanced imaging such as MRI or CT to diagnose neurologic defects in the 
neonates.  
These results are in agreement with another study from Pantoja and colleagues 
from the University of Puerto-Rico Medical Sciences Campus. They completed an in vivo 
study with rhesus macaques demonstrating that prior DENV immunity does not 
contribute to more severe disease in subsequent ZIKV infection.30 Comparing ZIKV 
infection in a group of four-dengue naïve versus a group of four dengue immune rhesus 
macaques, they found that the dengue immune cohort had fewer days of ZIKV viremia 
compared to the dengue naïve monkeys.30 They suggest therefore, that previous DENV 
exposure may aide in neutralization of ZIKV infection.  
First, the researchers sought out to confirm whether their samples would produce 
ZIKV ADE in vitro. They used two groups of four macaques each, one group infected 
with DENV-1 and the other infected with DENV-2. They took serum from the monkeys 
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at 30 and 60 days, and at 1, 1.5, and 2.5 years after the dengue infection. Then, to test if 
their antibodies enhanced ZIKV in vitro, they took serum from two DENV-1 infected and 
two from DENV-2 infected monkeys 2.5 years after DENV infection and in incubated it 
with the leukemic cell line K562 and then introduced Zika virus. They compared the 
levels of ZIKV viremia in this cell line to a group of K562 cells that were incubated with 
DENV naïve serum. They found that in the DENV-naïve group, less than 1% of cells 
were infected with ZIKV. 30 In the DENV-immune individuals there was 10-20% 
enhancement of ZIKV infection at low serum dilutions. More than 20% enhancement of 
ZIKV was seen in one DENV-2 immune subject. 30 Furthermore, these results are 
consistent with Dejnirsattasai, Primvayada, Paul, etc who have demonstrated similar 
findings that in vitro ADE of Zika virus can be adequately measured.27, 32, 28 
 Next, the investigators selected four DENV immune macaques who had cross-
reactive but non-neutralizing antibodies, and they infected them with ZIKV 2.8 years 
later. On post-infection-day (p.i.d) 30, all subjects had a significant increase in the cross-
reacting DENV IgG, and in the levels of anti-ZIKV NS1 (nonstructural proteins) IgG. 30 
IgM titers to ZIKV declined by p.i.d 30. They measured ZIKV viremia with quantitative 
real-time RT-PCR. The first four days post-infection, ZIKV RNA was present in both the 
DENV immune and DENV naïve groups, however, on day 5, three out of four DENV-
naïve subjects and one out of four DENV-immune monkeys had detectable RNA. 30 Then 
on day six, two out of four naive and three out of four immune macaques had detectable 
viremia. The DENV-immune monkeys had a shorter period of detectable viremia; only 
two out of four immune monkeys had vRNA during days 7-15 post-infection. This is in 
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direct contrast to the four DENV naïve monkeys all of whom had detectable ZIKV RNA 
for at least one day between days 7-15 post-infection. 30 Figure 5 from Pantoja et al’s 
original paper below demonstrates that there was no difference in numbers of viral 
genome copies after 30 days between the DENV-immune and DENV naïve subjects.  
 
Figure 3: Zika Virus Kinetics 30 
 
 To measure clinical manifestations of ZIKV infection, investigators monitored 
weight, external temperature and rectal temperature before and after ZIKV infection. No 
animal experienced changes in weight or external or rectal temperatures. Only one naïve 
monkey developed a temperature above 38.8°C. 30 On days 7, 15, and 30 complete blood 
count (CBC), blood chemistries, white blood cell counts, absolute numbers of 
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lymphocytes, neutrophils, and monocytes were measured. Investigators found that for 
both groups of subjects, lymphocytes, monocytes, and neutrophil counts decreased on 
day 7, but the only statistically significant drop was in the neutrophil count in the DENV-
immune macaques. 30 In addition, compared to baseline, the percent of monocytes 
increased in DENV-immune subjects on day 7. There were no apparent clinical signs of 
severe infection in seven out of the eight macaques. However, one of the DENV-immune 
macaques developed a nonpruritic skin rash. 30  
 From this work, Pantoja and colleagues make the following conclusions: in 
dengue immune individuals, cross-reactive antibodies are able to enhance ZIKV but not 
neutralize DENV in vitro. However, in vivo, those antibodies were unable to prolong 
ZIKV viremia, and in fact the ZIKV viremic period was shorter in dengue immune 
subjects. 30 Additionally, when Pantoja et al evaluated the T and B cell response to ZIKV 
infection, they found that neither the naïve nor DENV-immune monkeys experienced 
deficits in responding to ZIKV. 30 They found that the DENV-immune subjects had 
upregulated amounts of CD107a+ and CD8+ T cells after infection with ZIKV, 
demonstrating that previous DENV immunity promoted the ability of CD8+T cells to 
perform a cytotoxic role instead of enhancing the ZIKV production. 30 Furthermore, the 
authors present a strong in vivo study showing that no signs of ADE were apparent when 
DENV immune cohort is subsequently infected with ZIKV. 30 
 Despite Pantoja et al’s ability to demonstrate a lack of disease enhancement 
occurring in monkeys, they did not show how prior dengue virus immunity and Zika 
virus infection affects pregnancy, a key part of understanding the pathophysiology of the 
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virus. In order for the immune system to avoid rejection of the fetus the immune system 
is compromised in pregnancy; perhaps changes to baseline immunity has problematic 
effects on the fetus when ZIKV infection occurs.2 Moreover, Pantoja et al postulate that 
perhaps previous DENV immunity causes a more robust immune response and therefore 
the virus is unable to invade the fetal CNS.30 If these theories were true, then a study of 
prior DENV immunity in pregnant macaques would show that neonates are at decreased 
risk for congenital abnormalities. Future studies should examine this point and use a 
much larger study sample population. 
Other investigators have made similar conclusions about the lack convincing 
evidence pointing to ADE in ZIKV. Pantoja et al question the validity of Halstead’s 
findings on ADE using rhesus macaques from which much of the basis for the theory 
comes from.30 They believe that although he does show in rhesus macaques that prior 
dengue exposure cause subsequent viral enhancement of heterologous dengue serotypes, 
that the data lack statistical significance.30 Simmons et al in their study of Vietnamese 
mother-infant pairs exposed to dengue in utero highlight the discordance between dengue 
viremia, antibody titers, and severe effects after secondary dengue infection. 17 
Investigators agree that ADE after primary Dengue virus infection cannot alone explain 
the constellation of effects leading to Congenital Zika Syndrome. 17, 18 Variability in host 
immune responses and differences in viral strains of ZIKV contribute to enhanced 
neuropathology.37 While ADE may be a contributing factor there are additional 
components of the immune response that factor into the more severe outcomes of the 
recent ZIKV epidemics.  
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Investigators have also found conflicting results surrounding the role of 
antibodies. For example, Swanstrom et al identified a set of human mAbs isolated from 
DENV infected patients that neutralized ZIKV and even treated infection in a mouse 
model. The mAbs evaluated were against the envelope dimer epitope 1 (EDE1).33 
Swanstrom et al found that cross neutralizing antibodies EDE1 C8 and EDE1 C10 
reduced levels of ZIKV infection in human monocytes.33 To test if the same mAbs were 
effective in vivo, they used type I/II IFN receptor knockout mice susceptible to ZIKV 
infection. The mice were given EDE1 C10 or phosphate buffered saline (PBS) at 1 and 9 
days and then challenged with ZIKV. Although 60% of the mice given PBS died, 100% 
of mice given the mAbs EDE1 C10 survived. 33 The authors reported the surviving mice 
displayed no signs of illness and gained more weight than those surviving mice given the 
PBS injection.  They believe that these data signify a candidate for an immunoglobulin 
therapy that could be given to pregnant mothers infected with ZIKV similarly to the 
gamma globulin treatment used to reduce congenital defect in mothers infected with 
rubella. 33  
Swanstrom et al also tested 17 serum samples of individuals with primary DENV 
immune sera against ZIKV, and found that most of the primary sera did not neutralize 
ZIKV. In secondary DENV immune sera, all of the samples neutralized DENV-1,2,3, and 
15 out of 16 neutralized DENV-4, but had low or undetectable levels of ZIKV cross-
neutralizing antibodies. Only 6 out of 16 samples, or 38% of the individuals had 
measureable titers of antibodies that could neutralize ZIKV. 33 In sum, the investigators 
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showed that both primary and secondary DENV immune sera had low levels of ZIKV 
cross-neutralizing antibodies.  
While the investigators found that EDE1 monoclonal antibodies were effective in 
neutralizing ZIKV, they found that the DENV immune sera from human subjects broadly 
did not posses much neutralizing efficacy. 33 They question whether plasmablasts able to 
produce EDE1 type antibodies are made in all people, or if they depend on specific 
serotype infection and whether the plasmablasts eventually differentiate into memory B 
cells. 33 In addition, Swanstrom et al find that even in patients who had cross-neutralizing 
antibodies to three or more DENV serotypes, there was no cross-neutralization of 
ZIKV.33   
These data highlight the variability of responses found with DENV immune sera 
against ZIKV underscoring possible differences in host immunity that may contribute to 
the range of disease manifestations observed. While Swanstrom et al found that mAbs 
isolated from DENV immune sera against a specific antigen EDE1 are effective 
neutralizers of both DENV and ZIKV, why they exist in only some subjects and not all in 
others may contribute to why some pregnancies exhibit severe congenital defects, and 
others are unaffected.33 
Dr. Halstead’s 1973 paper on secondary DENV infection in monkeys examined 
the antibody responses in monkeys who had primary DENV infection and were exposed 
to a heterologous DENV. Using 118 rhesus macaques, he challenged monkeys at 2, 6, 12, 
and 26 weeks with a second virus and measured their clinical course for signs of severe 
dengue manifestations in addition to measuring their antibody titers.34 While he did find 
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several trends suggesting increased antibody production of the secondary virus, he did 
not report statistical significance for his findings making it difficult to evaluate the trends 
observed. 34 One of Halstead’s most important findings he says, is that two secondary 
DENV2 infections resulted in considerably more viremia than primary DENV-2 
infections, and this did not occur with other types of DENV. 34 However, he did not 
report the p values or any other measures of statistical significance so that the reader may 
understand if this was a true difference. Although these results have been replicated in 
other studies they have mostly been in vitro, and not representative of manifestations in 
humans.30 More in vivo studies must be carried out with preferably human subjects or 
non-human primates to evaluate both levels of viremia and antibody response in 
conjunction with clinical correlates.  
Cugola et al look to the genetics of Zika virus to examine the pathogenesis in a 
mouse model. They find that there is a gene expression profile that is correlated with 
increased cell death in the microcephalic mice brains infected with ZIKV.35 
Experimentally, they found that ZIKV could not cross the placenta in the C57BL/6 mice, 
most likely because of the robust production of IFN I/II produced in this mouse strain, 
which resist ZIKV infection. These variances in host immune response could explain 
why some pregnancies are not affected by ZIKV infection in pregnancy.35 Winkler et al 
have expanded on this idea; ZIKV is known to evade the type I IFN response in humans, 
but it is unable to do this in mice, and as such its pathogenesis is limited in this model.36 
To demonstrate this point, when investigators produced knockout mice that lacked the 
type I IFN response and only had adaptive immune system, when infected with ZIKV, 
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the mice lost weight, and ZIKV RNA was found in the brain and testes. 36 In addition, 
they found that CD8+ T cell responses in pregnant mice were decreased compared to 
non-pregnant mice. They extrapolate that the adaptive immune response is key in 
controlling ZIKV infection as is done in vaccination when the type I IFN reaction is 
decreased. 36   
Alternative hypotheses to explain the current increase in numbers of congenital 
defects seen with Zika virus may point to adaptive changes in the virus itself. There are 
two different strains of ZIKV that have been previously discussed, those being the Asian 
(seen in the Pacific) and the African strains.37 Only recently has ZIKV been seen to cause 
human-to-human transmission mainly through the Aedes aegypti vector.18 It has also been 
transmitted by the aedes albopticus, through sexual intercourse and vertically though 
perinatal infections.41 Investigators at the University of São Paulo hypothesize that some 
aspect of Zika virus must have changed to allow for better transmission amongst humans 
and mosquito vectors.37 Under the pressures of natural selection, viruses may include one 
codon over another translating to the same protein due to specific advantage that codon 
supplies. 37 Furthermore, de Melo Freire and colleagues hypothesize that the Asian type 
of ZIKV undergoes changes in nonstructural protein (NS1) codon to adapt to proteins 
highly expressed human housekeeping genes, genes that are essential for the cell to 
maintain basic function. 37 They propose that the adaptation to human housekeeping 
genes may permit enhanced viral replication and increase viral loads. 37 Looking at the 
genome sequences for the African and Asian lineages, they found that there was a 
selection at several codon sites that was seen in other mosquito transmitted viruses that 
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cause acute disease. They found that 91.8% of the residues of the NS1 proteins analyzed 
were identical showing that there was purifying selection for these viruses to infect 
humans. 37  
 When looking further at the Asian type of ZIKV at the codon adaptation index 
(CAI), investigators found that epidemic lineages had stronger bias on NS1 and NS4A 
genes and were more adapted to humans than the African strain. 37 In addition, they found 
that high CAI values for NS1 protein were indicative of improvement in the translational 
efficiency and higher viral loads seen in humans. 37 NS1 is involved in evading host cell 
immune responses, whereas NS4A may work to promote viral survival through blocking 
of cell-autopahgy.  
These results show that ZIKV has undergone changes to become more adept at 
human infection, possibly resulting in more severe infection. 37 This hypothesis makes 
intuitive sense given the historical evidence, which demonstrated very mild disease up 
until the first outbreak in French Polynesia.  In future studies, to provide more evidence 
to this endpoint, specific changes in NS1 proteins will have to be correlated to enhanced 
pathogenesis in animal subjects.	  
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METHODS 
 
Study design 
 The “Mãe Sana, Bebé Sana” (“Healthy Mother, Healthy Baby”) project will be a 
prospective cohort study involving pregnant women from Northeastern Brazil who have 
possible exposed to Dengue virus that are at risk for Zika virus infection. Participants will 
be screened over the course of their pregnancy for both Dengue and Zika virus infection 
via serologic testing, and clinical symptoms consistent with ZIKV with goal of evaluating 
the effects of previous dengue immunity and Zika infection on neonatal outcomes. This 
project will seek to understand if previous Dengue immunity and Zika virus infection 
lead an increased risk of developing congenital neurologic defects.  
Previous studies from Halai and Honein et al have documented fetal outcomes of 
ZIKV infection during pregnancy in both Brazil and the United States. Specifically, Halai 
et al looked at the associations between prior DENV immunity and ZIKV clinical 
severity, viremia, and risk of congenital defects. Their data showed no correlation 
between prior DENV immunity and enhanced ZIKV symptoms, viral load, or severity of 
congenital defects. One of the limitations of Halai et al’s study was that women were 
only included if they presented with rash and/or fever at any stage in pregnancy. This 
excludes subjects who may be Zika infected but asymptomatic, therefore underestimating 
the rate of Congenital Zika Syndrome. To account for this discrepancy, this study will 
include both symptomatic and asymptomatic women at risk for ZIKV infection during 
pregnancy. By prospectively following pregnancies and observing changes in antibody 
titers, viral load, prenatal ultrasound findings this will help elucidate whether timing of 
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infection during pregnancy affects neonatal outcomes. The objective of this study is to 
determine if an association exists between Congenital Zika Syndrome and prior Dengue 
virus exposure in women who are infected with Zika virus during pregnancy. 
 
Study population and sampling 
 This study will enroll pregnant women ages 18-45 years presenting for prenatal 
care at any of the trial sites in the nine Northeastern states of Brazil including: 
Pernambuco, Bahia, Alagoas, Ceará, Maranhão, Paraíba, Piauí, Rio Grande do Norte, and 
Sergipe where historically, the highest incidence of ZIKV infections occur. This sample 
will seek to enroll women who are at greatest risk for developing ZIKV infections. 
Patients will be followed for the duration of their pregnancy and will monitor their 
offspring during the first year of life thereafter.  
 
Inclusion/Exclusion criteria 
 
Healthy women ages 18-45 years who are presenting for prenatal care during their 
6th – 8th (up to 8 weeks and 0 days) week of pregnancy confirmed by transabdominal 
ultrasound and consistent with last menstrual period will be eligible for enrollment. A full 
medical history including routine prenatal screening for rubella, cytomegalovirus, 
toxoplasma gondii, syphilis, chikungunya, HIV, herpes simplex virus, parvovirus B19, 
listeria monocytogenes will be obtained. Any patient diagnosed with one of the above 
infections at the first screening will be excluded from the study. Subjects will also 
undergo testing for levels of folate. Any participants deemed folate deficient with levels 
less than 400ng/mL will be excluded (WHO). Women must be able to attend each clinic 
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visit every two weeks and be willing to provide blood samples. If genetic testing is done 
and reveals considerable risk for a genetic abnormality, documentation of these results 
will be considered into the analysis and women will be able to remain part of the study. 
In the event of spontaneous abortion, intrauterine fetal demise, or elective abortion 
women will pre-consent to the pathological examination of products of conception. 
Women who abuse drugs, alcohol, smoke cigarettes, or take certain medications that 
increase the risk of congenital abnormalities such as doxycycline, trimethoprim-
sulfamethoxazole, isotretinoin, valproic acid, and selective serotonin reuptake inhibitors 
will be excluded from this study. In addition, women with medical conditions such as 
diabetes known to cause neonatal congenital malformations will likewise be excluded 
from this study. Below is a table listing exclusion and inclusion criteria.  
 
Table 4: Inclusion and Exclusion Criteria 
 
Inclusion criteria Exclusion criteria 
- 6 to 8 weeks and 0 days of pregnancy 
confirmed by LMP and U/S 
-U/S must reveal normal for GA findings: 
fetal heartbeat, fetal pole, yolk sac 
-Women with inconclusive ultrasound, 
molar pregnancy, ectopic pregnancy, or 
beyond 8 weeks and 0 days upon 
presentation for prenatal care 
- Diagnosis of diabetes mellitus, 
uncontrolled hypo or hyperthyroidism, 
seizure disorder 
- Age 18-45 years  - History of taking teratogenic 
medications during pregnancy such as 
methotrexate, misoprostil, isotretionin, 
valproic acid, angiotensin converting 
enzyme inhibitors, angiotensin II 
antagonists, lithium, thalidomide, 
warfarin, diethylstilbestrol (DES) 
- No history of tobacco, alcohol, drug 
abuse during pregnancy 
-Diagnosis of rubella, cytomegalovirus, 
toxoplasma gondii, syphilis, 
chikungunya, HIV, herpes simplex 
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virus, parvovirus B19, listeria 
monocytogenes during pregnancy 
- Able to comply with study requirements 
including clinic visits and blood draws 
 
 
 
Exposure Groups  
Study participants will be allocated into two groups of four cohorts based on dengue 
exposure. The two groups will be 1. Dengue virus exposed and 2. Dengue virus naïve. 
Cohorts will be as follows:  
1. Zika infected, born with congenital defects 
2. Zika infected, no congenital defects 
3. Non-zika infected, born with congenital defects 
4. Non-Zika infected, no congenital defects  
 
Dengue naïve is defined as patients with negative serum ELISA and RT-PCR 
tests for Dengue serotypes 1-4. Dengue exposed is defined as any patient with positive 
serum RT-PCR and ELISA IgG or IgM testing to any of the four dengue serotypes. 
Likewise, Zika naïve is defined as having negative serum or urine RT-PCR and ELISA 
IgG or IgM testing for ZIKV. Zika immune is defined as having positive serum or urine 
RT-PCR and ELISA IgG or IgM testing for ZIKV. If patients contract ZIKV or DENV 
during their pregnancy, then they will be moved into the appropriate cohort study group. 
 
Study variables and measurement tools 
Study variables are the presence of Dengue virus infection and Zika virus 
infection in the mother. Outcomes are neurologic abnormalities of the neonate. As 
previously described, antibody titers determined by serum ELISA testing in addition to 
viral loads determined by serum or urine RT-PCR for ZIKV or just serum for DENV 
RNA will be indicative of infection. Per standard of care guidelines, all participants will 
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have transabdominal ultrasound evaluation performed with a 4-8mHz probe (Voluson 
730 Expert/Voluson E6, GE) by certified ultrasonographers upon enrollment in the study, 
and then at 20 weeks of gestation.  
Every month, for the duration of their pregnancy participants will have antibody 
titers drawn for DENV and ZIKV via ELISA testing with RT-PCR confirmation. At each 
visit where titers will be drawn, participants will be questioned if they have had any 
symptoms of zika virus infection: retro-orbital pain, myalgias, conjunctivitis, rash, or 
fever. Any patient should report symptoms outside of a clinic visit and have immediate 
testing for ZIKV performed. Once a subject has had confirmed zika virus or dengue virus 
infection with positive IgG or IgM ELISA and RT-PCR testing, then they will be placed 
into the corresponding study cohort.  
Regular pre-natal care visits can include study related procedures. Importantly, all 
participants should include full fetal anatomy ultrasound scans at 20 weeks, if 
abnormalities are seen consistent with those of prenatal zika infection or if patients had 
prior positive serum or urine testing for ZIKV, then maternal fetal medicine specialists 
will be consulted. Patients with negative ZIKV testing via blood, urine or ultrasound do 
not require additional ultrasounds outside of the standard of care. 
Upon delivery, neonates will have Zika and dengue antibody titers drawn, and 
they will have a full neurological assessment including head circumference 
measurements. Neonates will be assessed for one year to gain insight on neurologic, 
behavioral, or other health problems that may develop over the first year of life. Visits 
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will be conducted at 2 days, 1 month, 2, 4, 8, and 12 months to survey for any signs of 
neurologic deficits.  
Since the fetal outcomes will be based on physical exam findings and serum 
markers it is imperative clinicians make an accurate assessment of the physical exam. 
Trainings for clinicians on how to properly perform neonatal and infant neurologic exams 
will be held to certify uniformity across study sites.  
The primary outcomes to be measured will be the presence or absence of any 
neurologic deficits or physical abnormalities in the neonate or any pregnancy loss. 
Criteria for diagnosing a neonate as abnormal or normal are based on Halai and Brasil et 
al’s 2016 study and CDC criteria.31 Any pregnancy loss (stillbirth, miscarriage, or 
intrauterine fetal demise) will designate a pregnancy in the abnormal outcome group. 
Abnormal physical exam will include any focal neurologic deficits, hypertonicity, 
absence of reflexes, or microcephaly which is defined as head circumference less than 2 
standard deviations from the mean for age.52 The table below outlines five of the 
distinguishing features of congenital Zika syndrome for fetuses and infants infected with 
Zika virus before birth. The presence of any one of these features in a neonate will 
designate an abnormal outcome.  
Table 5: Features of Congenital Zika Syndrome 52 
Features of Congenital Zika Syndrome (adapted from CDC) 
- Severe microcephaly in which the skull has partially collapsed	
- Decreased brain tissue with a specific pattern of brain damage, including 
subcortical calcifications	
- Damage to the back of the eye, including macular scarring and focal pigmentary 
retinal mottling	
- Congenital contractures, such as clubfoot or arthrogryposis	
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- Hypertonia restricting body movement soon after birth	
		
Recruitment 
 Research assistants and clinicians will recruit patients at participating clinics. 
Research assistants will post signs with the study information around the clinics as well 
as make daily announcements in the waiting rooms alerting patients of the study. 
Research assistants will also individually approach women at their appointments to gage 
their interest, then if their labs, ultrasound and medical history are in accordance with 
research criteria then patients may be enrolled. The patient, research assistant, and 
clinician must all sign consent forms before the patient is enrolled in the study.   
 
Data collection 
Research assistants will gather data from the patient medical record and will be 
present for each study visit. When lab values are reported from each blood test and 
ultrasound, the research assistant will record these values into an excel spreadsheet for 
each patient. They will also be responsible for screening patients with a questionnaire 
about ZIKV infection symptoms. After subjects give birth, research assistants will also be 
responsible for including the neonatal data into the respective study participant excel 
sheet. 
 
	 	 	 	
	 	 	 	44	
Data analysis  
 This prospective cohort analysis will allocate study participants into two main 
groups, dengue naïve patients (seronegative) or dengue exposed patients (seropositive). 
The outcome measured whether or not their babies are born with abnormal exam findings 
based on the CDC criteria. Within these two arms, subjects will be further divided into 4 
categories: 	
1. Zika infected, born with abnormal exam findings 
2. Zika infected, no abnormal exam findings 
3. Non-Zika infected, born with abnormal exam findings  
4. Non-Zika infected, no abnormal exam findings 
 
Two tables illustrate how the data will be collected and how risk ratios will be calculated. 
  
Dengue Exposed 
Patients Infected 
with Zika virus 
Abnormal Exam Normal Exam Total 
Yes     
No    
Total    
 
Dengue Naive 
Patients Infected 
with Zika virus 
Abnormal Exam Normal Exam Total 
Yes     
No    
Total    
 
The alpha level and beta levels will be set at 0.05 and 80% power respectively per 
currently accepted standards. The WHO has assumed that the absolute risk of developing 
microcephaly was between 0.03 to 17.1% in 2015-2016 assuming two different infection 
rates of 10 and 50% in this region of Brazil.53 Assuming this level of prevalence, 
recruitment of study participants should not be difficult. The number of participants in 
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this study was calculated using the Australian National Statistics Calculator.  Confidence 
level was set to 95%, using an infinite population as the number of people infected with 
Zika virus is large. Confidence interval was defined as 0.05, and assuming a conservative 
10% proportion of the population will be infected with Zika virus modeling the WHO 
estimates, the sample size provided was 139 subjects.54  
Once the totals for each category have been summed, the cumulative incidence of 
will be calculated to then identify the relative risk for developing abnormal neurologic 
findings for each of the two groups. Then, the relative risk in the Dengue exposed group 
will be compared to the Dengue naïve group to properly define what the relative risk is of 
being Dengue exposed and Zika infected to having a child with neurologic deficits.  
Timeline and resources 
Year 1 Establishment Phase  
- Submit study protocol, hire research staff, and establish recruiting sites/partnering 
maternity hospitals, pre-natal care clinics, and pediatricians	
- Train study clinicians on proper neonatal neurologic exam	
 
Year 2 (21 months): enrollment and data collection phase 
- Research assistants will need office space within the clinics so they can enroll 
patients and collect data	
- Computers: one laptop computer for each research assistant	
- Will need access to ultrasounds, ultrasonographers	
- Lab space and personnel to run the RT-PCR and ELISA testing for prenatal labs	
- Principal investigator, co-investigators	
- 	
Year 3: Analysis phase 
- Research assistants will input data into SPSS	
- Statistician will analyze data	
- Principal investigators and research staff will meet to discuss results, conclusions 	
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Institutional Review Board 
This study involving vulnerable populations including pregnant women and 
neonates merits a full board review. Since this study is purely observational and does not 
involve any specific interventions, participants do not need to be counseled on how this 
study may impact their pregnancy. We will provide counseling to these women about 
how to best protect themselves against ZIKV infection as we would for any other 
pregnant patient. In addition, specific counseling about treatment options once ZIKV has 
been diagnosed will also be provided to patients so that they may make informed 
decisions taking into account risks and benefits. 
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CONCLUSION 	
Discussion 
 
 To study Zika virus in pregnancy is a difficult task given the varied clinical 
symptomology, varied accuracy of laboratory testing, and the continuing research on 
pathogenesis of the Zika virus infection. Moreover, the preceding literature review 
demonstrates that there are many factors, not only antibody dependent enhancement and 
previous Dengue virus immunity that play a role in the pathogenesis of congenital Zika 
syndrome. The “Mãe Sana, Bebé Sana” project is an attempt to gather more data about a 
possible association between previous Dengue immunity and Congenital Zika Syndrome. 
By including asymptomatic participants, this will broaden the scope of the study and has 
the potential to more precisely calculate the rate of neurologic defects in neonates 
infected with Zika. Limitations to this study is that it is challenging to infer a molecular 
mechanism from a human study. While Mãe Sana Bebé Sana looks at this association 
between Zika and Dengue clinically, it will not directly elucidate the relationship or 
interplay between the two different flaviviruses.  	
Summary 
 
Antibody dependent enhancement remains an important hypothesis to explain the 
rise in congenital defects due to ZIKV after primary DENV infection. Dr. Halstead’s 
research on dengue virus and original antigenic sin in Thailand laid important 
groundwork for this mechanism. Since then, investigators have examined specific 
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features of pathogenesis of Zika virus in pregnancy, viral genetics, and host genetic 
influences to determine why Congenital Zika Syndrome affects some and not all 
pregnancies. Clinical case reports in addition to many in vitro studies suggest that 
previous DENV immunity and low levels of cross-reactive antibodies can in fact increase 
levels of Zika virus in the blood leading to more acute clinical manifestations. It is 
equally likely that other factors such as changes in the viral genetic code and adaptive 
mutations leading to increased virulence in humans, and other genetic predispositions 
lead to more severe outcomes after Zika virus infection. In addition, the lack of in vivo 
evidence with either human or primate models makes the argument for ADE more 
difficult. It is clear that more study is necessary to further delineate the clear mechanism 
linking prior dengue immunity and Zika virus infection to Congenital Zika Syndrome. 
With more prospective cohort studies such as the Mãe Sana, Bebé Sana project including 
a larger population at risk for Zika virus will seek to pinpoint any association between 
Congenital Zika Syndrome and prior Dengue immunity.  
 
Public Health Significance  
Zika virus has a lasting devastating effect on not only individuals and families, 
but also on entire public health systems. Children born with Congenital Zika Syndrome 
require around-the-clock supervision, specialized medical care, occupational and physical 
therapy that is often times unavailable due to costs and/or regional access. It is estimated 
the cost of outbreaks of Zika virus in Latin America and the Caribbean could reach US$7 
to 18 billion from 2015 to 2017.55 Once scientists discovered Zika virus was sexually 
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transmitted, there has been increased pressure from public health systems to encourage 
access to birth control, challenging conservative traditions and belief systems. In many 
countries where abortion is illegal or effectively inaccessible, people are left with no 
choice but to carry to term pregnancies which may have no quality of life and who may 
die shortly after birth. Additionally, vector control measures using pesticides and 
community water control remains as important as ever in countries with a high burden of 
mosquito-transmitted diseases.  
As discussed previously, investigators are concerned the effect prior exposure to 
Dengue virus through immunization may have on rates of Zika virus infection given the 
evidence for Antibody Dependent Enhancement. Hopefully, with the introduction of the 
Dengvaxia vaccine there will not be an associated increase in cases of severe Dengue, 
Zika, or Congenital Zika Syndrome. Zika virus has become not only a medical and public 
health crisis, it intersects with government, environmental policy, reproductive health 
justice, social justice, and traditional value systems. Future goals to control Zika virus 
must be multifaceted, involving communities, officials, health care providers, and 
scientists.  
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APPENDIX 	
Overview of Zika Virus  
 
Epidemiology 
Since ZIKV was first isolated from a rhesus macaque in Uganda 1947 it was not 
known to cause severe manifestations. The first humans infected with Zika virus were 
from Nigeria in 1953 where it caused mild fever.40 The virus remained dormant until 
2007 when finally, Zika virus reached the Yap Islands of Micronesia where 74.6% of the 
population was infected.40 Another 32,000 people were suspected to have been infected 
with Zika virus in the French Polynesia epidemic of 2013, and the first associated cases 
of Guillain-Barré Syndrome and fetal microcephaly were identified. 40 The spread of Zika 
virus then rapidly accelerated when it reached Northeastern Brazil in 2015. In March 
2015, Zika virus caused an outbreak of exanthemous illness.41 By December 2015, there 
were an estimated number of 1.3 million suspected cases throughout Brazil, and in 
February 2016 there were approximately 4,300 cases of microcephaly documented in 
Brazil.42 One year later, Zika virus had spread to 33 countries in the Americas. 40 It is 
important to note Zika virus is endemic in the same areas as dengue virus and 
Chikungunya viruses, and share the same vectors, the Aedes mosquitoe. Currently, Zika 
virus is endemic in the Pacific, Caribbean, and the Americas. 
Zika Virus Background Information 
Zika virus, member of the flaviviridae family is a relative of dengue virus, yellow 
fever virus, Japanese encephalitis, West Nile virus, and Hepatitis C virus.25 It is a 11kb 
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positive sense RNA, enveloped virus and is transmitted via the ubiquitous Aedes aegypti 
and Aedes albopticus mosquitoes found throughout North and South America as well as 
Asia.40 Transmission occurs through bites by infected mosquitoes, perinatally, and 
through sexual intercourse. Interestingly, ZIKV is the only arbovirus that can also be 
transmitted through sexual intercourse (between heterosexual and homosexual couples).40 
Zika virus RNA has been isolated from blood, urine, semen, female genital tract 
secretions, and breast milk.40 Zika’s commonalities with other flaviviruses has important 
implications for its mechanism of pathogenesis as will be later described.  
Clinical Manifestations 
The most common symptoms associated with Zika virus are myalgias and arthralgias 
in the hands and feet, mild fever, pruritic rash with erythematous papules on the face, 
trunk, extremities, palms and soles, conjunctivitis, retro-orbital eye pain, and headaches.43 
Some individuals have mild symptoms for approximately 2-7 days or no symptoms at all. 
43 One of the challenges to surveillance of Zika virus is that the symptoms are often times 
similar to other viruses such as chikungunya and dengue virus.40 Clinical distinction 
between these viruses remains a challenge; thus, serologic testing remains the mainstay 
of definitive diagnosis of ZIKV infection.40 
Adverse Fetal Outcomes  
Due to the tropism for neuroprogenitor cells, systems most commonly affected in 
Congenital Zika Syndrome are the central nervous system (CNS). Neurologic defects 
such as microcephaly, brain calcifications, neural tube defects, anencephaly, and 
decreased brain parenchymal volume are some of the most common and are seen on a 
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wide spectrum of severity.10, 40 Due to CNS deficiencies and motor neurons affects 
congenital contractures (arthrogryposis), hyper/hypotonia, seizures, and spasticity are 
often seen. Fetal growth restriction may manifest in clubfoot and other positional 
abnormalities. 16, 40  Intrauterine fetal death resulting in miscarriage or stillbirth due to 
possible placental insufficiency produced by Zika infection of the placenta later in 
pregnancy has also been observed.9, 17  
 Data from a number of studies have shown the greatest risk of fetal anomalies is 
associated with infection in the 1st or 2nd trimester of pregnancy.3, 31 Despite this 
increased risk in early pregnancy, no period of gestation is free from risk of Zika virus 
infection.  
Investigators have questioned the validity of data used to calculate risks of 
congenital Zika virus syndrome. It is possible the number of Zika infected infants is 
underestimated due to the inability to detect some fetal abnormalities prenatally such as 
ocular abnormalities like glaucoma, retinal dysplasia, or even hearing loss.44 Overall 
estimates for any congenital abnormality in the fetus resulting from Zika infection ranges 
from 10-42%.3 The large variability in these data may result from variation in populations 
studied, the range of clinical abnormalities included, and the case definition of Zika 
infection whether it was suspected or confirmed.3  
 
Congenital Defect Definition 
Microcephaly -Small head for gestational age and 
sex, 2 SD below the mean or <3 
percentile for gestational age and 
sex,  
- Overall risk of anomalies in 
pregnancy is estimated at 6-42% 
	 	 	 	
	 	 	 	53	
CNS abnormalities -Calcifications, abnormal gyral 
patterns, decreased brain 
parenchymal volume, neural tube 
defects: anencephaly, 
encephalocele, spina bifida  
Other Abnormalities  Joint contractures, club foot 
Fetal death Hydrops, placental insufficiency 
Postnatal complications - Ocular abnormalities:  retinal 
dysplasia, nystagmus, glaucoma, 
not detectable prenatally  
- Hearing loss, neurologic/ 
positional abnormalities- 
hyper/hypotonia, spasticity, 
seizures, irritability 
 
 
 
Guillain-Barré Syndrome  
In addition to the range of congenital abnormalities seen in neonates, there have 
also been accounts of Guillain-Barré Syndrome (GBS) in Colombia, Brazil, and French 
Polynesia. It is a smaller minority of individuals who develop GBS after infection with 
Zika virus. A case-control study done in French Polynesia during the 2013-2014 
epidemic found the incidence of GBS to be 2.4 cases per 10,000 Zika virus infections.45 
Notably, 95% of patients with GBS had antibodies suggesting prior dengue virus 
infection; however, this did not differ significantly from the 89 and 83% seropositivity in 
the two control groups in the study.45 This literature review will later discuss how prior 
dengue virus exposure is an important factor in the discussion of clinical effects of ZIKV 
infection. Another case study from Colombia found that 32 of 37 patients with GBS also 
had some evidence of a recent DENV infection from the presence of cross-reactive IgM, 
IgG, or both types of antibodies. They suggest that the development of GBS was linked 
to having previous dengue virus infection.45 It is important to note however, that in this 
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case control study there were 5 subjects with GBS who had no evidence of a prior dengue 
viral infection.46 
 
Diagnostics 
Diagnostic tools are based on whether the exposure was more or less than 2 weeks 
ago, and whether this may have been a chronic exposure or a limited instance. Briefly, 
Zika viral RNA can be tested through serum or urine NAT or ELISA tests for IgM or 
IgG. If there are cases where IgM or NAT tests are equivocal, then plaque reduction 
neutralization tests (PRNT) are warranted.47 The main challenges to ZIKV testing are that 
the window for identification of viral RNA in blood or urine by PCR is only within first 2 
weeks of infection and viremia is typically low.41, 47 Due to serologic cross reactivity with 
dengue viruses 1-4 serotypes, i.e. preexisting dengue antibodies from past symptomatic 
or asymptomatic infection can give false positive results for Zika virus, and past Zika 
infection can cause positive dengue results.40 Therefore, ACOG recommends labs where 
combined Zika virus real time reverse transcriptase PCR and IgM and plaque reduction 
neutralization test (PRNT).47 Additionally, fetal ultrasonography is major modality to 
screen for congenital Zika virus infections. MRI is more sensitive for fetal brain 
abnormalities and is recommended in all women who test positive for Zika regardless of 
neonatal outcome.47  
Treatment 
Care of Zika infected patients is supportive. Fluids, acetaminophen to relieve pain 
and/or fever can be administered. Patients should avoid aspirin and other NSAIDs to 
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reduce risk of hemorrhage. In addition, women who present greater than 32 weeks of 
gestation should refrains from NSAIDS due to the risk of premature closure of the ductus 
arteriosus. 47 Fortunately, there are several promising studies going on currently to 
evaluate vaccine candidates. Sofosbuvir and other anti-viral medications are also being 
tested for treatment of Zika infection.49  
 
Prevention  
 Public health departments have stressed a multifaceted approach to prevention of 
Zika virus infection, especially in pregnant women. Zika virus presents a unique 
challenge in that it is both carried by mosquitos and is sexually transmitted. Therefore, 
prevention must be a multi-pronged effort aimed at contraception for those people who 
are truly not considering pregnancy, reducing sexual transmission with barrier methods, 
and vector control of mosquitos. The Zika virus epidemic has also forced public health 
departments to make policy decisions to recommend contraception and even recommend 
delaying pregnancy. Currently, the CDC recommends waiting 6 weeks to conceive for 
women and 8 weeks for men after possible exposure to Zika virus.41 These 
recommendations represent large behavioral changes especially in areas where 
contraception access is limited. 
Vector control 
As with many arboviruses, the best prevention is to protect from mosquito bites 
themselves by using mosquito nets at night while sleeping, protective clothing such as 
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long sleeves and long pants, and the eradication of small bodies of water in the 
community, which can be prime locations for mosquito breeding.41, 43  
 
 
Dengue Virus 
The antibody dependent enhancement theory describes Dengue virus (DENV) 
playing an essential role in priming the immune system for enhanced ZIKV infection. A 
brief discussion of DENV will highlight important facts and discuss the viral replication 
process essential to ADE.  
DENV and ZIKV both belong to the flaviviridae family, co circulate in similar regions of 
the world, and have similar disease sequelae.25 Four different serotypes of DENV exist: 
1, 2, 3, and 4. DENV is also transmitted by the Aedes aegypti mosquito, which serves as a 
vector for ZIKV. Dengue fever, also known as “break-bone fever” leads to a spectrum of 
symptoms ranging from mild muscle aches and bone pain to headache, retro-orbital pain, 
nausea, vomiting, and fever to fatal hemorrhagic disease and shock.50 Important 
differences between DENV and ZIKV are that ZIKV produces a maculopapular rash and 
conjunctivitis, and typically dengue virus does not produce either of these features.25 
Dengue disease is known to become increasingly severe after serial infections with 
different serotypes.25 Antibody dependent enhancement is also a proposed mechanism for 
how serial dengue infections produce more severe disease. 
Diagnosis 
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The diagnosis of dengue fever is mostly based on clinical signs and symptoms for 
individuals residing in dengue endemic areas. Diagnostic tools such as IgM serology or 
MAC-ELISA (IgM antibody capture enzyme-linked immunoabsorbent assay) are also 
helpful. Importantly, there is significant cross-reactivity between DENV ELISA testing 
and those for other flaviviruses, such as West Nile Virus, Japanese encephalitis, and Zika 
virus, which may often confound diagnosis.47 
 
Epidemiology  
An estimated 390 million DENV infections occur each year, and 96 million have 
recognizable clinical features.51 Symptomatic dengue infections are more clinically 
apparent in adults than children (WHO).51 In the Americas in 2015, there were 2.35 
million cases reported, 10,200 cases were classified as severe and caused 1,181 deaths.51  
 
Flavivirus Lifecycle 
Exploration of the flavivirus life cycle will demonstrate how viral replication 
lends itself to antigenic variance. Broadly, the flavivirus attaches to host cells and is taken 
up via receptor-mediated endocytosis.25 Once inside a host macrophage, membrane 
fusion is triggered by the acidic pH in the endosome to release the uncoated viral RNA. 
Then the positive stranded RNA is read and translated by host ribosomes into viral 
proteins. At the endoplasmic reticulum, viral assembly occurs forming immature and 
mature virions, which then go through exocytosis.25 
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Two proteins prM and E are important to the antigenic variability of the flavivirus 
family. After assembly of virions and packaging in the endoplasmic reticulum, the acidic 
pH in the transgolgi network (TGN) leads to cleavage of the precursor membrane protein 
(prM) by cell protease furin into pr and M proteins.25 The structural precursor membrane 
protein prM is a chaperone protein closely associated with the envelope protein (E). PrM 
guides the appropriate folding of the E protein and to prevents premature fusion inside 
the producing cell. E protein’s function is to facilitate cell entry by fusing virus and cell 
membranes.  When inside the TGN, the cleaved pr protein stays associated with viral 
particles and then falls off once it reaches the neutral pH of extracellular environment, 
creating mature infectious virions. Subviral particles (SVPs) formed as by-product of 
virion assembly are exocytosed like whole virions; however, they display prM and E 
dimers but contain no viral RNA, thus they are not infectious.25  
Furthermore, the flavivirus replication cycle occurs such that different proteins 
are accessible on the surface leading to greater antigenic variability. The partial cleavage 
of prM is typical of flaviviruses giving rise to antigenic differences among individual 
viruses. Its important to note that completely immature particles can also become 
infectious when endocytosed. 25  Viruses that are partially immature or incompletely 
cleaved results in more effective antibody neutralization because specific protein 
sequences are more accessible which can in turn cause cell-to cell type differences in 
neutralizing antibody titers.25 Furthermore, this amount of variability could contribute to 
differences in flavivirus immunity amongst individuals. 25   
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Another important part of pathogenesis of flaviviruses is how they infect host 
cells. Most recent studies show that TIM proteins (T cell immunoglobulin mucin domain) 
and TAM (Tyro3, Axl, and Mer) receptors facilitate passage of flaviviruses into host cell. 
25 Normally, the TIM/TAM receptors are responsible for recognizing cellular debris from 
apoptosis to signal to phagocytes to engulf material, but flaviviruses take advantage of 
these receptors in order to get preferentially taken up by phagocytes. This process is 
called apoptotic mimicry. 25 This is a mechanism not unique to ZIKV but is used by the 
flavivirus family.  
Once virus-antibody complexes are endocytosed by Monocytes, macrophages, 
dendritic cells via Fc receptors, flaviviruses can suppress innate antiviral responses 
through Ab-dependent Fcγ receptor-mediated signaling” (intrinsic ADE) which can lead 
to increased replication of the infecting virus. 25 Furthermore, incompletely neutralized 
virus within the Fc receptor presenting cell is able to fuse with the endosome, and then 
can start virus production. If immune complexes with completely neutralized virus fail to 
fuse with the endosome, viral replication will not progress. 25 Overall, antigenic variation 
in viral production which may contribute to the varied response from the host immune 
system. Further discussion of these viral proteins will clarify this point.  
 
Appendix 2:  
Appendix 2: Pathogenesis of Zika Virus Infection in Murine and Human Models 
Mechanism of Zika virus pathogenesis in utero 
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Before discussion of antibody dependent enhancement, it is vital to review the 
pathophysiology of ZIKV. This section will explore what is known about the effects of 
Zika virus on the placenta, and also Zika viral tropism for fetal neuroprognitor cells. 
Placenta Physiology 
Adibi and colleagues at the University of Pittsburgh have tried to reconcile the 
data that has been generated to further characterize the role of the placenta in ZIKV 
congenital defects.9 They postulate that cytokines or other immune modulators that are 
produced by the mother negatively affect the fetus. Adibi et al put forth two additional 
hypotheses: the transfer hypothesis and the placental mediated hypothesis. 9 First, the 
transfer hypothesis states that ZIKV is neurotropic and via the placenta, virions directly 
access the developing fetal brain. 9 This is supported by the fact that many in vivo studies 
with animals, primates, and case reports have shown ZIKV antigens and RNA in fetal 
brain tissue.11 However, the caveat is that in the early first trimester the embryo is well 
shielded from maternal blood flow.9 Adibi states that it is possible that the virus, through 
uterine gland secretions seeps through trophoblastic plugs that block maternal blood flow, 
or that in infection during the preconceptive period the virus affects the amniotic and yolk 
sac as they develop. 9 Adibi, similarly to Coyne et al, postulate that Zika virus could 
infect the trophoblastic cells, and that during viral replication, the trophoblastic 
endoplasmic reticulum may package virions in vesicles which may then be directed 
toward fetal neuroprogenitor cells.9 
Second, is the placental mediation hypothesis, where the placenta mounts an 
inflammatory response against ZIKV contributing to brain defects secondary to placental 
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insufficiency. Investigators believe this is a highly probable mechanism because in later 
stages of pregnancy, to access the fetus ZIKV would have to penetrate two layers of cells, 
the syncytiotrophoblasts and cytotrophoblasts until reaching macrophages and entering 
the fetal capillary. 9 Quicke’s 2016 in vitro study shows that placental macrophages 
(Hofbauer cells) are easier to infect than trophoblasts.12 Furthermore, Quicke et al show 
that placental macrophages allow infection of ZIKV, and that when this occurs, cells 
upregulate IFNa and cytokines IL-6, IP-10, MCP-1, and type 1 interferon genes. It 
follows that macrophages could be facilitating transfer since ZIKV does not cause cell 
death in Hofbauer cells, and that cytokines actively causing inflammation could provide 
ZIKV camoflauge from the immune system. 12 
In a newly published article in Science, Chavali and colleagues describe the 
neurotropism of ZIKV for the MSI-1 protein in its ability to facilitate 
neuropathogenesis.13 Chavali et al found that congenital microcephaly involves mutations 
in neural precursor proteins, Musashi-1 (MSI1). MSI-1 was found to bind ZIKV RNA 
resulting in increased viral replication.13 In addition, MSI1 impairs RNA from binding to 
neural stem cells causing problems in brain development in fetus. Chavali et al found that 
the higher the number of MSI1 cells, the higher the rate of zika viral replication, and the 
higher the numbers of cell death.13 Incidentally, investigators found that in experimental  
mice, there were high levels of MSI1 expression in the testes, which could explain why 
the virus is sexually transmitted.13 This description of ZIKV neurotropism for the MSI-1 
protein provides concrete evidence as to why particular tissues are implicated in neonatal 
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congenital defects and in the future may help to explain the mechanism of how ZIKV 
causes Guillain-Barré Syndrome.  
In sum, it is difficult to disentangle the pathogenesis of microcephaly due to the 
changing nature of the placenta, the multifaceted effects of the virus, and the virus’ 
specific neurotropism. Future study will absolutely be necessary to understand the 
timeline of infection and on a molecular level how Zika virus exerts its pathogenesis. For 
more information on viruses that cause congenital defects in pregnancy, refer to the 
appendix. 
Studies on neonatal animal models:  
Mice studies have provided valuable information showing the effects of Zika 
virus on mice pups. Vermillion et al designed an animal study where they infected mice 
with ZIKV at either early or established placentation periods and observed the effects on 
the fetal or neonatal mice.14 They demonstrated that inoculation of ZIKV at embryonic 
day 10  (E10) which correlates to completion of placentation in humans and when all 
trophoblastic cells are present, significantly reduced life expectancy and increased 
placental inflammation, dysfunction, and reduced thickness of the neonatal cortex. 14 On 
autopsy of the infected mice and progeny, Zika virions were identified in trophoblasts, 
placental endothelial cells, and in fetal endothelial, microglial and neuroprogenitor cells 
in the brain. 14 In the placenta, they found that Zika infection caused increased production 
of IFN-β, an inflammatory cytokine, and heightened activation of IFN-genes 48 hours 
post infection.14 
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When mice were inoculated with ZIKV at E10 as opposed to E14 (corresponding 
to the end of the 3rd trimester in humans), fetal viability 48 hours post inoculation was 
significantly decreased.14 48 hours post infection the E14 mice had lower amounts of 
RNA detected in placenta than the E10 mice, and showed no infectious virus in the 
placenta. 14 In contrast, E10 infected mice had large amounts of ZIKV RNA, and 
infectious virions in fetal brains. At 96 hours comparing the two types of mice, the trend 
was similar; the earlier in the gestational the mice were infected, the greater the 
transmission to the fetus, and the less viable fetuses became. 14 Immunohisotchemistry 
results of the fetus and placenta 48 hours post inoculation at E10 showed significant loss 
of definition between layers of placenta cells, hemorrhage and mixing of maternal and 
fetal blood demonstrating a highly compromised trophoblast-endothelial barrier. In the 
fetal brains, Zika virus antigen was seen localizing in CD34+ fetal endothelial cells, 
microglia and neural progenitor cells.14 
To evaluate the effects of Zika virus infection in term neonates, a small group of 
Zika infected mice were followed to term, until the pups were delivered. The pup’s brain 
tissue was evaluated for cortical thickness as a measure of brain development and the 
presence of Iba-1+ microglia as a marker of neural inflammation. Compared to sham 
infected mice, the Zika infected pups had reduced cortical thickness, and increased Iba-
1+ activated microglia, suggesting brain inflammation. 14 This finding is consistent with 
other in vivo studies and clinical studies showing that first trimester inoculation with Zika 
virus is particularly detrimental to fetal growth and results in the highest percentage of 
microcephaly and other neurologic complications.3 
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Looking more specifically at brain pathology, Wu et al in a mice study show via 
immunohistochemistry that ZIKV infects radial glial cells, the principal progenitor cells 
for cortex development in the dorsal ventricular zone.15 Immunocompetent pregnant mice 
received an intraperitoneal injection of ZIKV on embryonic day 13.5 and their pups were 
evaluated for ZIKV infection and neuropathology at birth. After staining the mice brains 
with Ki67, a marker for mitosis in growing cells, they found that the ZIKV infection 
reduced the number of Ki67 stained cells in the subventricular and intermediate zones of 
the brain, leading the researchers to believe that ZIKV inhibited proliferation of cortical 
neural progenitor cells. There was also a decrease in the neural progenitor pool after 
ZIKV infection, further supporting the data that ZIKV infection causes cell death of 
neural progenitor cells and inhibits cell cycle progression. 15 Investigators also found 
ZIKV RNA in 5 out of 9 placentas, which lead them to believe that ZIKV can efficiently 
cross the fetal-placental barrier. 15  
Autopsy reports in humans have shown similar results to animal studies regarding 
neurotropism of the Zika virus. Brazilian investigator, Martines et al, evaluated pathology 
specimens from five cases in 2015 where ZIKV infection was deemed to have been the 
cause of death.11 The cases included two newborns with microcephaly and severe 
arthrogyrposis who died just after birth, one 2 month-old baby, and two placentas from 
spontaneous abortions. Using immunohistochemistry, mouse-anti ZIKV antibody, and 
RT-PCR investigators found that viral antigens in glial cells and neurons associated with 
microcalcifications in the three neonates with microcephaly. 11 Other brain malformations 
observed were lissencephaly, cerebellar hypoplasia, and ventriculomegaly. Congenital 
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contractures, craniofacial malformations, pulmonary hypoplasia were also found. 
Histopathological findings revealed microcalcifications, microglial nodules and cell 
necrosis. One of the placentas showed zika antigens in the chorionic villi. All five case 
sample tissues were positive for ZIKV by RT-PCR. 11  
These pregnancies shared several key commonalities. All women had fever and 
rash in first trimester of pregnancy and were from similar geographic regions. 11 Different 
from other viral infections causing microcephaly such as cytomegalovirus (CMV) and 
herpes simplex virus (HSV), there was no substantial inflammation or cytopathic viral 
effect appreciated in the brain tissue.11 They deduced that Zika virus causes an 
inflammatory response similar to what is seen in congenital rubella syndrome. 11 In 
addition, Zika virus was only seen in CNS tissues, as opposed to mouse models, which 
showed infection of many different organs.14 Both ZIKV and TORCH pathogens can 
cause fetal akinesia deformation sequence (FADS)/ severe arthrogryposis. FADS is a 
group of characteristics such as intrauterine growth restriction (IUGR), multiple joint 
contractures, facial anomalies, underdevelopment of lungs (hypoplasia) usually due to 
lack of movement in utero.16 Martines et al’s work supports the evidence that ZIKV 
infection is associated with spontaneous abortion and specific congenital malformations 
secondary to its detrimental effects on CNS tissues.  	
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